Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
| ▸ | TUBB | P07437 | 1/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.39 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.39 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.39 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.39 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.39 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4400503 | 0.90 | ALDH1A1 (0.43) | KDM4EKMT2AMEN1L3MBTL1TUBB4A | |
| SCHEMBL4403582 | 0.88 | SIRT1 (0.45) | KDM4EKMT2AMEN1TUBB4ATUBB | |
| SCHEMBL4400380 | 0.82 | SIRT1 (0.44) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4405031 | 0.81 | SIRT1 (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL14194790 | 0.76 | SIRT1 (0.45) | KMT2AMEN1GAATUBB4ATUBB | |
| SCHEMBL29819713 | 0.76 | TUBB4A (0.58) | KDM4EKMT2AMEN1GAATUBB4A | |
| SCHEMBL4322899 | 0.76 | TUBB4A (0.58) | KDM4EKMT2AMEN1GAATUBB4A | |
| SCHEMBL5635745 | 0.73 | CPT1A (0.43) | GAAMAPT | |
| SCHEMBL14194793 | 0.73 | TUBB4A (0.50) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3478415 | 0.73 | TUBB4A (0.45) | KDM4EKMT2AMEN1L3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390029-B1 | PHENYLINDOLES FOR THE TREATMENT OF HIV | IDENIX CAYMAN LTD (KY) | 2009-12-16 | — | — | EP | disclosed |
| US-20070293668-A1 | Phenylindoles for the treatment of HIV | LACOLLA PAULO | 2007-12-20 | — | — | US | disclosed |
| US-20040180888-A1 | Phenylindoles for the treatment of HIV | IDENIX PHARMACEUTICALS INC. | 2004-09-16 | — | — | US | disclosed |
| US-6710068-B2 | PHENYLSULFONYLINODLES USEFUL FOR THE TREATMENT OF HIV IN HUMANS AND OTHER HOST ANIMALS | IDENIX PHARMACEUTICALS, INC. | 2004-03-23 | — | — | US | disclosed |
| US-20020193415-A1 | Phenylindoles for the treatment of HIV | IDENIX PHARMACEUTICALS INC. | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293668-A1 | Phenylindoles for the treatment of HIV | DUT, NQO1, ENTPD5 | KDM4E 1393/4885KMT2A 3276/4885MEN1 3850/4885 |
| US-20020193415-A1 | Phenylindoles for the treatment of HIV | DUT, NQO1, ENTPD5 | KDM4E 1393/4885KMT2A 3276/4885MEN1 3850/4885 |
| US-20040180888-A1 | Phenylindoles for the treatment of HIV | DUT, NQO1, ENTPD5 | KDM4E 1393/4885KMT2A 3276/4885MEN1 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.